Tag:
velaglucerase alfa
Latest Headlines
Latest Headlines
Shire ready to undercut Cerezyme price by 15%
A price war could be shaping up for Gaucher disease. With its PDUFA date looming, Shire says that it plans to market its new therapy under the name VPRIV (it was developed as velaglucerase alfa), and
Who's up for a big FDA approval decision in the first half?
Few events can move a biotech stock quite like an FDA decision on a new drug app. And given the agency's rep for somewhat unpredictable behavior, there's no such thing as a sure thing. All of which
Shire races to FDA with new Gaucher drug app
Racing to plug a market gap created by the sudden shortage of Cerezyme, the UK's Shire says that it has filed for FDA approval of its new therapy for Gaucher disease ahead of schedule. The developer
